Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Genzyme Corporation
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of PROs
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Safety, Efficacy, and Pharmacokinetics Study of Recombinant Human Acid Sphingomyelinase in Patients With Acid Sphingomyelinase Deficiency Sicurezza, Efficacia e Analisi di Farmacocinetica della sfingomielinasi acida ricombinante umana in pazienti con carenza di sfingomielinasi acida
The primary objective is to evaluate the safety, efficacy, and pharmacokinetics of different doses of rhASM administered intravenously (IV) every 2 weeks for 52 weeks. L’obiettivo primario di...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis
To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation and its Affiliates
MAJ Il y a 4 ans
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Determine whether mipomersen (ISIS 301012) significantly reduces atherogenic lipid levels in patients with severe heterozygous familial hypercholesterolemia (severe HeFH), defined as low-density lipop...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
GZ/SAR402671 in Combination with Cerezyme in Adult Patients with Gaucher Disease Type 3
Part 1: -Evaluate central nervous system (CNS) biomarkers in Gaucher disease (GD) type 3 (GD3) that distinguish GD3 from Gaucher disease type 1 (GD1). -Screen adult GD3 patients who qualify for trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
To evaluate long-term safety of alemtuzumab
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
To assess the long-term safety of vatelizumab in MS patients
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
A long-term study of olipudase alfa in patients with acid sphingomyelinase deficiency
The primary objective of this study is to obtain data regarding the safety of olipudase alfa in patients with acid sphingomyelinase deficiency (ASMD) who are exposed to long-term treatment with olipud...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
NeoGAA Extension Study
Long-term safety and pharmacokinetics (PK) of neoGAA
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
Evaluation of efficacy and safety of vandetanib in patients with advanced papillary or poorly differentiated thyroid cancer
To determine the efficacy (as assessed by progression free survival (PFS) ) of vandetanib when compared to placebo in patients with differentiated thyroid cancer that is either locally advanced or met...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
1
2
3
Suivant